Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.61 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | FAAH | O00519 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1532853 | 0.95 | KMT2A (0.57) | ABL1RIN1KMT2AMEN1KDM4E | |
| SCHEMBL1575998 | 0.92 | ABL1 (0.58) | ABL1RIN1KMT2AMEN1KDM4E | |
| SCHEMBL12736015 | 0.87 | KDM4E (0.56) | KMT2AKDM4EPKMGPR119FAAH | |
| SCHEMBL12736038 | 0.87 | KDM4E (0.52) | ABL1RIN1KMT2AMEN1KDM4E | |
| SCHEMBL12736051 | 0.86 | GPR119 (0.59) | KMT2AMEN1KDM4EPKMGPR119 | |
| SCHEMBL12736039 | 0.86 | ABL1 (0.53) | ABL1RIN1KMT2AMEN1KDM4E | |
| SCHEMBL31747488 | 0.86 | GPR119 (0.62) | KMT2AKDM4EPKMGPR119FAAH | |
| SCHEMBL12736012 | 0.85 | KDM4E (0.54) | KMT2AKDM4EPKMGPR119FAAH | |
| SCHEMBL20015389 | 0.84 | GPR119 (0.60) | KMT2AMEN1KDM4EPKMGPR119 | |
| SCHEMBL30824890 | 0.84 | GPR119 (0.58) | KDM4EPKMGPR119FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2607362-B1 | Piperidine and piperazine carboxylates as FAAH inhibitors | ASTELLAS PHARMA INC (JP) | 2014-12-31 | — | — | EP | disclosed |
| US-7919494-B2 | Pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate compound | ASTELLAS PHARMA, INC. (JP) | 2011-04-05 | — | — | US | disclosed |
| US-7919494-B2 | Pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate compound | ASTELLAS PHARMA, INC. (JP) | 2011-04-05 | — | — | US | disclosed |
| US-7919495-B2 | Pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate compound | ASTELLAS PHARMA, INC. (JP) | 2011-04-05 | — | — | US | disclosed |
| US-7919495-B2 | Pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate compound | ASTELLAS PHARMA, INC. (JP) | 2011-04-05 | — | — | US | disclosed |
| US-7915261-B2 | Pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate compound | ASTELLAS PHARMA, INC. (JP) | 2011-03-29 | — | — | US | disclosed |
| US-7915261-B2 | Pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate compound | ASTELLAS PHARMA, INC. (JP) | 2011-03-29 | — | — | US | disclosed |
| US-20100009971-A1 | Pyridyl Non-Aromatic Nitrogen-Containing Heterocyclic-1-Carboxylate Compound | ASTELLAS PHARMA INC. (JP) | 2010-01-14 | — | — | US | disclosed |
| US-20100009971-A1 | Pyridyl Non-Aromatic Nitrogen-Containing Heterocyclic-1-Carboxylate Compound | ASTELLAS PHARMA INC. (JP) | 2010-01-14 | — | — | US | disclosed |
| US-20100009972-A1 | Pyridyl Non-Aromatic Nitrogen-Containing Heterocyclic-1-Carboxylate Compound | ASTELLAS PHARMA INC. (JP) | 2010-01-14 | — | — | US | disclosed |
| US-20100009972-A1 | Pyridyl Non-Aromatic Nitrogen-Containing Heterocyclic-1-Carboxylate Compound | ASTELLAS PHARMA INC. (JP) | 2010-01-14 | — | — | US | disclosed |
| US-20080306046-A1 | Pyridyl Non-Aromatic Nitrogen-Containing Heterocyclic-1-Carboxylate Derivative | FMC CORPORATION (US) | 2008-12-11 | — | — | US | disclosed |
| US-20080306046-A1 | Pyridyl Non-Aromatic Nitrogen-Containing Heterocyclic-1-Carboxylate Derivative | FMC CORPORATION (US) | 2008-12-11 | — | — | US | disclosed |
| EP-1849773-A1 | PYRIDYL NON-AROMATIC NITROGENATED HETEROCYCLIC-1-CARBOXYLATE ESTER DERIVATIVE | Astellas Pharma Inc. (JP) | 2007-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306046-A1 | Pyridyl Non-Aromatic Nitrogen-Containing Heterocyclic-1-Carboxylate Derivative | FAAH, FAAH2, APEH | ABL1 3459/4885RIN1 2216/4885KMT2A 2467/4885 |
| US-20100009972-A1 | Pyridyl Non-Aromatic Nitrogen-Containing Heterocyclic-1-Carboxylate Compound | FAAH, FAAH2, CNR2 | ABL1 3106/4885RIN1 1246/4885KMT2A 2469/4885 |
| US-20100009971-A1 | Pyridyl Non-Aromatic Nitrogen-Containing Heterocyclic-1-Carboxylate Compound | FAAH, FAAH2, CNR1 | ABL1 3093/4885RIN1 1198/4885KMT2A 2502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.